HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

2- (1H- indol- 3- yl)- 3- (pyridin- 3- yl)acrylonitrile

an MKLP-2 inhibitor; structure in first source

Also Known As:

paprotrain

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 140
- Nitriles: 233
  - Acrylonitrile: 239
    - 2-(1H-indol-3-yl)-3-(pyridin-3-yl)acrylonitrile: 2
Heterocyclic Compounds: 207
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 205
      - 2-(1H-indol-3-yl)-3-(pyridin-3-yl)acrylonitrile: 2

Experts

1.	Daigo, Yataro: 1 article (01/2020)
2.	Miyagi, Yohei: 1 article (01/2020)
3.	Nakamura, Masako: 1 article (01/2020)
4.	Takano, Atsushi: 1 article (01/2020)
5.	Thang, Phung Manh: 1 article (01/2020)
6.	Tsevegjav, Bayarbat: 1 article (01/2020)
7.	Yamashita, Toshinari: 1 article (01/2020)
8.	Yokose, Tomoyuki: 1 article (01/2020)
9.	Zhu, Ming: 1 article (01/2020)
10.	Bougeret, Cécile: 1 article (02/2016)

Related Diseases

1.	Neoplasms (Cancer) 02/15/2016 - "Upon testing in different cancer cell lines, we find that the more potent paprotrain analog is also more active than paprotrain in 10 different cancer cell lines. "
2.	Breast Neoplasms (Breast Cancer) 01/01/2020 - "The suppression of endogenous KIF20A expression using small interfering ribonucleic acids or via treatment with paprotrain, a selective inhibitor of KIF20A, significantly inhibited breast cancer cell growth through cell cycle arrest at the G2/M phase and subsequent mitotic cell death. "

Related Drugs and Biologics

1.	RNA (Ribonucleic Acid)